ROR1 and B-cell chronic lymphocytic leukemia: Several monoclonal antibody (mAb) therapies showed heterogenous results against ROR1 in CLL, with low levels of cellular toxicity reported in CLL and MCL cell lines treated with anti-ROR1 mAbs [102, 103].